Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer

Mod Pathol. 2010 May;23 Suppl 2:S52-9. doi: 10.1038/modpathol.2010.55.

Abstract

There are currently three prognostic/predictive biomarkers used in routine clinical management of patients with breast cancer, and their assessment is mandatory. They include estrogen receptor-alpha (ERalpha), progesterone receptor (PgR), and the HER2 oncogene/oncoprotein. This paper briefly reviews the assessment of ERalpha, PgR, and HER2 in breast cancer, emphasizing recent progress and persistent controversies.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor / analysis*
  • Biomarkers, Tumor / genetics
  • Biomarkers, Tumor / metabolism
  • Breast Neoplasms / genetics*
  • Breast Neoplasms / metabolism*
  • Breast Neoplasms / pathology
  • Estrogen Receptor alpha / biosynthesis*
  • Estrogen Receptor alpha / genetics
  • Female
  • Genes, erbB-2
  • Genetic Predisposition to Disease
  • Humans
  • Immunohistochemistry
  • Receptor, ErbB-2 / biosynthesis*
  • Receptor, ErbB-2 / genetics
  • Receptors, Progesterone / biosynthesis
  • Receptors, Progesterone / genetics

Substances

  • Biomarkers, Tumor
  • Estrogen Receptor alpha
  • Receptors, Progesterone
  • ERBB2 protein, human
  • Receptor, ErbB-2